Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis
Authors
Keywords
-
Journal
DRUG SAFETY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-03-04
DOI
10.1007/s40264-019-00799-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010
- (2018) Simon Faissner et al. CNS DRUGS
- Challenges and Opportunities for the Traceability of (Biological) Medicinal Products
- (2018) Kevin Klein et al. DRUG SAFETY
- Alemtuzumab depletion failure can occur in multiple sclerosis
- (2018) Nicolas Dubuisson et al. IMMUNOLOGY
- Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
- (2018) E. C. Tallantyre et al. JOURNAL OF NEUROLOGY
- Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations
- (2018) Virginia Devonshire et al. JOURNAL OF NEUROLOGY
- End of the road for daclizumab in multiple sclerosis
- (2018) The Lancet LANCET
- Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned
- (2018) Eugene O Major et al. LANCET NEUROLOGY
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
- (2018) Alan J Thompson et al. LANCET NEUROLOGY
- Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
- (2018) Mika Saarela et al. NEUROLOGY
- Acute acalculous cholecystitis
- (2018) David Croteau et al. NEUROLOGY
- Multiple Sclerosis
- (2018) Daniel S. Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
- (2018) Mathias Granqvist et al. JAMA Neurology
- Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System
- (2018) Ippazio Cosimo Antonazzo et al. Multiple Sclerosis Journal
- Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report
- (2018) C Lapucci et al. Multiple Sclerosis and Related Disorders
- Treatment of multiple sclerosis — success from bench to bedside
- (2018) Mar Tintore et al. Nature Reviews Neurology
- Vitiligo after alemtuzumab treatment
- (2018) Tobias Ruck et al. NEUROLOGY
- Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis
- (2017) Marinella Clerico et al. Expert Opinion On Drug Safety
- Natalizumab in Multiple Sclerosis: Long-Term Management
- (2017) Marinella Clerico et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab
- (2017) Evangelos A.A. Christou et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy
- (2017) Aiden Haghikia et al. LANCET NEUROLOGY
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
- (2017) Tomas Kalincik et al. LANCET NEUROLOGY
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
- (2017) Pei-Ran Ho et al. LANCET NEUROLOGY
- Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis
- (2017) Marwan Sheikh-Taha et al. Multiple Sclerosis Journal
- Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
- (2017) Nicky Dunn et al. Multiple Sclerosis Journal
- Neuroinflammation: Synapses pruned in lupus
- (2017) Sarah McGlasson et al. NATURE
- Biologics registers in RA: methodological aspects, current role and future applications
- (2017) Elena Nikiphorou et al. Nature Reviews Rheumatology
- Alemtuzumab CARE-MS I 5-year follow-up
- (2017) Eva Havrdova et al. NEUROLOGY
- Evaluating the safety of β-interferons in MS
- (2017) Hilda J.I. de Jong et al. NEUROLOGY
- Natalizumab-associated PML
- (2017) Nicholas Schwab et al. NEUROLOGY
- PML in natalizumab-treated multiple sclerosis
- (2017) Ellen M. Mowry et al. NEUROLOGY
- Alemtuzumab CARE-MS II 5-year follow-up
- (2017) Alasdair J. Coles et al. NEUROLOGY
- No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML
- (2017) Doriana Landi et al. NEUROLOGY
- Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution of biological agents: how established drugs can become less safe
- (2017) Nicole Casadevall et al. BMJ-British Medical Journal
- Evolution of biological agents: how established drugs can become less safe
- (2017) Nicole Casadevall et al. BMJ-British Medical Journal
- Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis
- (2017) Marwan Sheikh-Taha et al. Multiple Sclerosis Journal
- Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
- (2017) Nicky Dunn et al. Multiple Sclerosis Journal
- Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis
- (2017) Keh Yann et al. Multiple Sclerosis and Related Disorders
- Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity—Report of a Case and Review of the Literature
- (2017) Julian Zimmermann et al. Frontiers in Neurology
- Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
- (2016) James G. Krueger et al. ADVANCES IN THERAPY
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature
- (2016) D. Kavanagh et al. BLOOD
- Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis
- (2016) María Rosario Blasco et al. JOURNAL OF NEUROLOGY
- Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy
- (2016) Robert Hoepner et al. Multiple Sclerosis Journal
- Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal
- (2016) Catherine Larochelle et al. Multiple Sclerosis Journal
- Interferon α or β: which is the culprit in autoimmune disease?
- (2016) Mary K. Crow Nature Reviews Rheumatology
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
- (2016) Douglas L. Arnold et al. NEUROLOGY
- The BSRBR-RA at 15 years
- (2016) Elaine M. Dennison et al. RHEUMATOLOGY
- Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy
- (2016) Robert Hoepner et al. Multiple Sclerosis Journal
- Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal
- (2016) Catherine Larochelle et al. Multiple Sclerosis Journal
- Interferon β associated nephropathy in a Multiple Sclerosis patient: A case and review
- (2016) Musa Ozturk et al. Multiple Sclerosis and Related Disorders
- Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
- (2016) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a
- (2015) Ali-Frédéric Ben-Amor et al. ADVANCES IN THERAPY
- Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
- (2015) Annette Kolb-Mäurer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
- (2015) Daniela Rau et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long?
- (2015) Sara Barmettler et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy
- (2015) Tuan Dong-Si et al. JOURNAL OF NEUROVIROLOGY
- Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator
- (2015) Jacqueline Palace et al. LANCET NEUROLOGY
- Type I interferon dysregulation and neurological disease
- (2015) Sarah McGlasson et al. Nature Reviews Neurology
- Progress and Hurdles for Follow-on Biologics
- (2015) Ameet Sarpatwari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2015) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natalizumab-induced hepatic injury: A case report and review of literature
- (2015) A Antezana et al. Multiple Sclerosis and Related Disorders
- Traceability of biologicals: present challenges in pharmacovigilance
- (2014) Niels S Vermeer et al. Expert Opinion On Drug Safety
- Thyroid papillary carcinoma after alemtuzumab therapy for MS
- (2014) Richard Ibitoye et al. JOURNAL OF NEUROLOGY
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β
- (2014) Catherine Larochelle et al. Multiple Sclerosis Journal
- Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity
- (2014) O. Kousin-Ezewu et al. NEUROLOGY
- Syndromes of Thrombotic Microangiopathy
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Thrombotic Microangiopathy Associated with Interferon Beta
- (2014) David Hunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypogammaglobulinaemia after rituximab treatment--incidence and outcomes
- (2014) M. Makatsori et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
- UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model
- (2014) Jacqueline Palace et al. BMJ Open
- Progressive multifocal leukoencephalopathy after natalizumab discontinuation
- (2013) Andrew J. Fine et al. ANNALS OF NEUROLOGY
- Biosimilars in rheumatology: the wind of change
- (2013) Christian K Schneider ANNALS OF THE RHEUMATIC DISEASES
- The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA
- (2013) Jakub Závada et al. ANNALS OF THE RHEUMATIC DISEASES
- Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients
- (2013) A. J. Fine et al. CLINICAL INFECTIOUS DISEASES
- Central nervous system lymphoma associated with natalizumab
- (2013) Angelika Na et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Early development of anti-natalizumab antibodies in MS patients
- (2013) B. Oliver-Martos et al. JOURNAL OF NEUROLOGY
- Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis
- (2013) L. Azzopardi et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis
- (2013) Heinz Wiendl et al. Nature Reviews Neurology
- Fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies
- (2013) A. Svenningsson et al. NEUROLOGY
- Immune competence after alemtuzumab treatment of multiple sclerosis
- (2013) C. L. McCarthy et al. NEUROLOGY
- Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
- (2013) J. L. Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
- (2013) Julien Mahe et al. Drug Design Development and Therapy
- Presymptomatic Diagnosis with MRI and Adequate Treatment Ameliorate the Outcome after Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2013) Hans Lindå et al. Frontiers in Neurology
- Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy
- (2012) Tarek A. Yousry et al. ANNALS OF NEUROLOGY
- Biologic registries in rheumatology: Lessons learned and expectations for the future
- (2012) Ori Elkayam et al. AUTOIMMUNITY REVIEWS
- Breathlessness, night sweats, and weight loss on natalizumab
- (2012) D Dahdaleh et al. LANCET
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
- (2012) Anke Vennegoor et al. Multiple Sclerosis Journal
- Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab
- (2012) T. Button et al. Multiple Sclerosis Journal
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing–remitting multiple sclerosis
- (2012) David Meyer et al. Multiple Sclerosis and Related Disorders
- Current and emerging therapies in multiple sclerosis: a systematic review
- (2012) Wanda Castro-Borrero et al. Therapeutic Advances in Neurological Disorders
- A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
- (2011) A. Cuker et al. BLOOD
- Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
- (2011) Grant A Hill-Cawthorne et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria
- (2011) Hans-Peter Hartung et al. LANCET NEUROLOGY
- Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
- (2011) M. Cossburn et al. NEUROLOGY
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
- (2011) P. W. O'Connor et al. NEUROLOGY
- Alemtuzumab Induction in Renal Transplantation
- (2011) Michael J. Hanaway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sarcoidosis complicating treatment with natalizumab for Crohn's disease
- (2011) C. A. Parisinos et al. THORAX
- Assessment of JC virus DNA in blood and urine from natalizumab-treated patients
- (2010) Richard A. Rudick et al. ANNALS OF NEUROLOGY
- Anti-JC virus antibodies: Implications for PML Risk Stratification
- (2010) Leonid Gorelik et al. ANNALS OF NEUROLOGY
- Evolution of Nevi During Treatment With Natalizumab
- (2010) Emeline Castela et al. ARCHIVES OF DERMATOLOGY
- Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
- (2010) Augusto Miravalle et al. ARCHIVES OF NEUROLOGY
- Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity
- (2010) Joanne L. Jones et al. BRAIN
- A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type
- (2010) Shekoufeh Nikfar et al. CLINICAL THERAPEUTICS
- A Novel Strategy To Reduce the Immunogenicity of Biological Therapies
- (2010) J. Somerfield et al. JOURNAL OF IMMUNOLOGY
- Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
- (2010) Chris H Polman et al. LANCET NEUROLOGY
- Combination therapy in multiple sclerosis
- (2010) Devon Conway et al. LANCET NEUROLOGY
- An approach to natalizumab hypersensitivity: a case series of induction of tolerance
- (2010) Marie Camacho-Halili et al. Multiple Sclerosis Journal
- Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells
- (2009) Andrew J. Rech et al. Annals of the New York Academy of Sciences
- Type I IFNs and their role in the development of autoimmune diseases
- (2009) Laura M Burdick et al. Expert Opinion On Drug Safety
- B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
- (2009) Sara A. J. Thompson et al. JOURNAL OF CLINICAL IMMUNOLOGY
- IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
- (2009) Joanne L. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
- (2009) Kenneth R Carson et al. LANCET ONCOLOGY
- Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?
- (2009) Roberto Bergamaschi et al. Multiple Sclerosis Journal
- Absence of MxA induction by interferon in patients with MS reflects complete loss of bioactivity
- (2009) D. Hesse et al. NEUROLOGY
- Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
- (2009) Hans Lindå et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy
- (2008) Kerstin Hellwig et al. ARCHIVES OF NEUROLOGY
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started